BAM Logo

Molecular Testing in Glioma (IDH1/2, MGMT)

EPTIS factsheet 794165 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts794165 https://www.eptis.bam.de/pts794165

PT provider
Based in Australia
Language(s) English
Remarks This module qualitatively assesses laboratory performance in the detection, reporting and interpretation of isocitrate dehydrogenase (IDH) 1 and 2 gene variants, and methylguanine-DNA Methyltransferase (MGMT) promoter methylation in glioma. What's new: This program is previously called IDH Mutation Analysis in Glioma. MGMT promoter methylation is now included in this module.
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
FFPE tissue (patient derived) FFPE DNA extraction Single H&E stained section
MGMT gene methylation Three unstained 10µM sections (mounted)
IDH1 gene variants Molecular genetic testing
IDH2 gene variants -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (3 cases per survey/1 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
Suite 201/8 Herbert Street
St Leonards, 2065

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5